S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
All the trading advice you’ve ever received boils down to this (Ad)
What is carbon capture and why does it keep coming up at COP28?
Polish truck drivers are blocking the border with Ukraine. It's hurting on the battlefield
All the trading advice you’ve ever received boils down to this (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Peek inside Joe Biden's campaign fundraisers, where big money mingles with old jokes in swanky homes
All the trading advice you’ve ever received boils down to this (Ad)
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Consumer product agency issues warning on small magnetic balls linked to deaths
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
All the trading advice you’ve ever received boils down to this (Ad)
What is carbon capture and why does it keep coming up at COP28?
Polish truck drivers are blocking the border with Ukraine. It's hurting on the battlefield
All the trading advice you’ve ever received boils down to this (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Peek inside Joe Biden's campaign fundraisers, where big money mingles with old jokes in swanky homes
All the trading advice you’ve ever received boils down to this (Ad)
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Consumer product agency issues warning on small magnetic balls linked to deaths
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
All the trading advice you’ve ever received boils down to this (Ad)
What is carbon capture and why does it keep coming up at COP28?
Polish truck drivers are blocking the border with Ukraine. It's hurting on the battlefield
All the trading advice you’ve ever received boils down to this (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Peek inside Joe Biden's campaign fundraisers, where big money mingles with old jokes in swanky homes
All the trading advice you’ve ever received boils down to this (Ad)
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Consumer product agency issues warning on small magnetic balls linked to deaths
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
All the trading advice you’ve ever received boils down to this (Ad)
What is carbon capture and why does it keep coming up at COP28?
Polish truck drivers are blocking the border with Ukraine. It's hurting on the battlefield
All the trading advice you’ve ever received boils down to this (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Peek inside Joe Biden's campaign fundraisers, where big money mingles with old jokes in swanky homes
All the trading advice you’ve ever received boils down to this (Ad)
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Consumer product agency issues warning on small magnetic balls linked to deaths

West Pharmaceutical Services Stock Price, News & Analysis (NYSE:WST)

$342.24
+1.05 (+0.31%)
(As of 12/8/2023 ET)
Compare
Today's Range
$338.30
$342.27
50-Day Range
$318.29
$392.21
52-Week Range
$224.15
$415.73
Volume
470,668 shs
Average Volume
366,557 shs
Market Capitalization
$25.32 billion
P/E Ratio
46.19
Dividend Yield
0.23%
Price Target
$381.25

West Pharmaceutical Services MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
11.4% Upside
$381.25 Price Target
Short Interest
Healthy
1.74% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.53
Upright™ Environmental Score
News Sentiment
0.95mentions of West Pharmaceutical Services in the last 14 days
Based on 13 Articles This Week
Insider Trading
Selling Shares
$737,157 Sold Last Quarter
Proj. Earnings Growth
9.48%
From $8.02 to $8.78 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.69 out of 5 stars

Medical Sector

85th out of 932 stocks

Surgical & Medical Instruments Industry

18th out of 93 stocks


WST stock logo

About West Pharmaceutical Services Stock (NYSE:WST)

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. The company serves pharmaceutical, diagnostic, and medical device companies. It distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. The company was incorporated in 1923 and is headquartered in Exton, Pennsylvania.

WST Stock Price History

WST Stock News Headlines

3 Dividend Champions with room for dividend growth (WST)
Dividend Champions that have payout ratios below 20%, like these three stocks, can be an incredibly compelling choice for buy-and-hold dividend investors.
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
West Announces First-Quarter 2024 Dividend
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
11 Best November Dividend Stocks To Buy
West Pharmaceutical Services: The Run Might Be Over
West to Host Third-Quarter 2023 Conference Call
See More Headlines
Receive WST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for West Pharmaceutical Services and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/26/2023
Ex-Dividend for 11/15 Dividend
11/07/2023
Dividend Payable
11/15/2023
Today
12/09/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/15/2024

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Supplies
Sector
Medical
CUSIP
95530610
Employees
13,550
Year Founded
1923

Price Target and Rating

Average Stock Price Target
$381.25
High Stock Price Target
$440.00
Low Stock Price Target
$290.00
Potential Upside/Downside
+11.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$585.90 million
Pretax Margin
22.50%

Debt

Sales & Book Value

Annual Sales
$2.89 billion
Cash Flow
$10.43 per share
Book Value
$36.22 per share

Miscellaneous

Free Float
73,154,000
Market Cap
$25.32 billion
Optionable
Optionable
Beta
1.08

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Should I Buy West Pharmaceutical Services Stock? WST Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of West Pharmaceutical Services was last updated on Tuesday, November 28, 2023 at 1:30 PM.

Pros

Here are some ways that investors could benefit from investing in West Pharmaceutical Services, Inc.:

  • Strong market presence: West Pharmaceutical Services, Inc. is a well-established company in the surgical and medical instruments industry. With a history dating back to 1923, the company has built a solid reputation and has a wide customer base.
  • Global reach: The company operates in multiple regions, including the Americas, Europe, the Middle East, Africa, and the Asia Pacific. This global presence provides opportunities for growth and diversification.
  • Innovative products: West Pharmaceutical Services, Inc. offers a range of containment and delivery systems for injectable drugs and healthcare products. The company's proprietary products, such as stoppers and seals for injectable packaging systems, syringe and cartridge components, and self-injection devices, are designed to enhance the safe delivery of drugs and meet the needs of pharmaceutical companies.
  • Integrated solutions: In addition to its product offerings, West Pharmaceutical Services, Inc. provides integrated solutions, including analytical lab services, regulatory expertise, and after-sales technical support. These services add value to the company's offerings and can attract customers looking for comprehensive solutions.
  • Recent financial performance: While specific financial data is not provided in the given context, recent financial performance can be an important factor for investors. Investors should consider analyzing the company's financial statements, including revenue growth, profitability, and cash flow, to assess its financial health and potential for future returns.

Cons

Investors should be bearish about investing in West Pharmaceutical Services, Inc. for these reasons:

  • Competition: The surgical and medical instruments industry is highly competitive, with numerous players vying for market share. West Pharmaceutical Services, Inc. faces competition from both large and small companies, which could impact its market position and profitability.
  • Regulatory risks: As a company operating in the healthcare industry, West Pharmaceutical Services, Inc. is subject to various regulations and compliance requirements. Changes in regulations or failure to comply with existing regulations could have a negative impact on the company's operations and financial performance.
  • Dependency on pharmaceutical industry: West Pharmaceutical Services, Inc. primarily serves biologic, generic, and pharmaceutical drug companies. The company's success is closely tied to the performance of the pharmaceutical industry. Any downturn or challenges faced by the pharmaceutical industry could affect the demand for West Pharmaceutical Services' products.
  • Currency exchange risks: With its global operations, West Pharmaceutical Services, Inc. is exposed to currency exchange risks. Fluctuations in exchange rates can impact the company's financial results, especially when a significant portion of its revenue or expenses is denominated in foreign currencies.
  • Market volatility: Like any publicly traded company, West Pharmaceutical Services, Inc.'s stock price is subject to market volatility. Investors should be aware of the potential for price fluctuations and consider their risk tolerance before investing.














WST Stock Analysis - Frequently Asked Questions

Should I buy or sell West Pharmaceutical Services stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for West Pharmaceutical Services in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" WST shares.
View WST analyst ratings
or view top-rated stocks.

What is West Pharmaceutical Services' stock price target for 2024?

4 Wall Street analysts have issued 1-year price targets for West Pharmaceutical Services' stock. Their WST share price targets range from $290.00 to $440.00. On average, they expect the company's stock price to reach $381.25 in the next twelve months. This suggests a possible upside of 11.4% from the stock's current price.
View analysts price targets for WST
or view top-rated stocks among Wall Street analysts.

How have WST shares performed in 2023?

West Pharmaceutical Services' stock was trading at $235.35 at the start of the year. Since then, WST stock has increased by 45.4% and is now trading at $342.24.
View the best growth stocks for 2023 here
.

Are investors shorting West Pharmaceutical Services?

West Pharmaceutical Services saw a increase in short interest in November. As of November 15th, there was short interest totaling 1,280,000 shares, an increase of 35.9% from the October 31st total of 942,000 shares. Based on an average daily volume of 363,100 shares, the days-to-cover ratio is presently 3.5 days. Currently, 1.7% of the company's stock are short sold.
View West Pharmaceutical Services' Short Interest
.

When is West Pharmaceutical Services' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 15th 2024.
View our WST earnings forecast
.

How were West Pharmaceutical Services' earnings last quarter?

West Pharmaceutical Services, Inc. (NYSE:WST) posted its earnings results on Thursday, October, 26th. The medical instruments supplier reported $2.16 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.86 by $0.30. The medical instruments supplier had revenue of $747.40 million for the quarter, compared to the consensus estimate of $750.31 million. West Pharmaceutical Services had a net margin of 19.11% and a trailing twelve-month return on equity of 21.86%. The business's revenue for the quarter was up 8.8% on a year-over-year basis. During the same period last year, the business earned $2.03 EPS.
Read the conference call transcript
.

How often does West Pharmaceutical Services pay dividends? What is the dividend yield for West Pharmaceutical Services?

West Pharmaceutical Services announced a quarterly dividend on Wednesday, December 6th. Shareholders of record on Wednesday, January 31st will be given a dividend of $0.20 per share on Wednesday, February 7th. This represents a $0.80 annualized dividend and a dividend yield of 0.23%. The ex-dividend date of this dividend is Tuesday, January 30th.
Read our dividend analysis for WST
.

Is West Pharmaceutical Services a good dividend stock?

West Pharmaceutical Services (NYSE:WST) pays an annual dividend of $0.80 per share and currently has a dividend yield of 0.23%. The company has been increasing its dividend for 31 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 10.80%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, WST will have a dividend payout ratio of 9.11% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for WST.

What is Eric M. Green's approval rating as West Pharmaceutical Services' CEO?

107 employees have rated West Pharmaceutical Services Chief Executive Officer Eric M. Green on Glassdoor.com. Eric M. Green has an approval rating of 75% among the company's employees. 60.0% of employees surveyed would recommend working at West Pharmaceutical Services to a friend.

What other stocks do shareholders of West Pharmaceutical Services own?

Based on aggregate information from My MarketBeat watchlists, some companies that other West Pharmaceutical Services investors own include NVIDIA (NVDA), Johnson & Johnson (JNJ), AbbVie (ABBV), Walt Disney (DIS), Home Depot (HD), Visa (V), Alibaba Group (BABA), McDonald's (MCD), Netflix (NFLX) and PepsiCo (PEP).

Who are West Pharmaceutical Services' major shareholders?

West Pharmaceutical Services' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Bank of New York Mellon Corp (4.59%), Artisan Partners Limited Partnership (2.15%), Brown Advisory Inc. (1.77%), FMR LLC (1.48%), Bamco Inc. NY (1.42%) and Northern Trust Corp (1.09%). Insiders that own company stock include Annette F Favorite, Bernard Birkett, Chad Winters, Charles Witherspoon, Cindy Reiss-Clark, Eric Mark Green, Quintin J Lai, Silji Abraham and Thomas W Hofmann.
View institutional ownership trends
.

How do I buy shares of West Pharmaceutical Services?

Shares of WST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does West Pharmaceutical Services have any subsidiaries?
The following companies are subsidiares of West Pharmaceutical Services: Drug Delivery Assets From Plastef Investissements SA, Medimop Medical Projects Ltd., TGPR Holdings Limited, Tech Group Europe Limited (dba West), Tech Group Grand Rapids Inc. (dba West), The Tech Group Inc., W.P.S.F. Limited, WD SG Pte. Ltd., West Analytical Services LLC, West Contract Manufacturing LLC, West Pharma. Services IL Ltd., West Pharmaceutical Packaging (China) Company Ltd., West Pharmaceutical Packaging India Private Limited, West Pharmaceutical Products Ireland Ltd., West Pharmaceutical Services AZ Inc., West Pharmaceutical Services Argentina S.A., West Pharmaceutical Services Asia Ltd., West Pharmaceutical Services Australia Pty. Ltd., West Pharmaceutical Services Beograd d.o.o., West Pharmaceutical Services Brasil Ltda., West Pharmaceutical Services Colombia S.A.S., West Pharmaceutical Services Cornwall Limited, West Pharmaceutical Services Danmark A/S, West Pharmaceutical Services Delaware Acquisition Inc., West Pharmaceutical Services Deutschland GmbH Co KG, West Pharmaceutical Services France S.A.S., West Pharmaceutical Services Group Limited, West Pharmaceutical Services Hispania S.A., West Pharmaceutical Services Holding Danmark ApS, West Pharmaceutical Services Holding France SAS, West Pharmaceutical Services Holding GmbH, West Pharmaceutical Services Holding II GmbH, West Pharmaceutical Services Holding Ireland North Ltd., West Pharmaceutical Services Holding Ireland South Ltd., West Pharmaceutical Services Holding Japan GK, West Pharmaceutical Services Holdings Ltd., West Pharmaceutical Services Italia S.r.L., West Pharmaceutical Services Korea Ltd., West Pharmaceutical Services Lakewood Inc., West Pharmaceutical Services Normandie SAS, West Pharmaceutical Services Shanghai Medical Rubber Products Co. Ltd., West Pharmaceutical Services Singapore (Holding) Pte. Limited, West Pharmaceutical Services Singapore Pte. Ltd., West Pharmaceutical Services Switzerland GmbH, West Pharmaceutical Services Venezuela C.A., West Pharmaceutical Services Verwaltungs GmbH, West Pharmaceutical Services of Delaware Inc., and West Pharmaceutical Services of Florida Inc..
Read More
This page (NYSE:WST) was last updated on 12/9/2023 by MarketBeat.com Staff

My Account -